At Chinook Therapeutics, we believe our work should be informed by patients and for patients. Our partnerships with leading Patient Advocacy Organizations enable us to better understand our patients and their needs. We’re also committed to improving patient access and representation in our clinical trials through financial assistance or compensation for out-of-pocket costs. We thank patients and their families for their interest in our clinical trials. Clinical trial participation makes our research and advances in the treatment of kidney disease possible.
If you have any questions about our clinical trials, please speak with your physician or contact email@example.com.
|Indication||Program*||Trial Number||Trial Name|
|IgA Nephropathy (IgAN)||Atrasentan||NCT04573478||Phase 3 Study of Atrasentan in IgA Nephropathy (The ALIGN Study)|
|IgA Nephropathy (IgAN)||Atrasentan||NCT04573920||Phase 2 Basket Study of Atrasentan in Proteinuric Glomerular Disease (The AFFINITY Study)|
|IgA Nephropathy (IgAN)||BION-1301||NCT03945318||A Phase 1, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy|
|Alport Syndrome||Atrasentan||NCT04573920||Phase 2 Basket Study of Atrasentan in Proteinuric Glomerular Disease (The AFFINITY Study)|
|Primary Focal Segmental Glomerulosclerosis (FSGS)||Atrasentan||NCT04573920||Phase 2 Basket Study of Atrasentan in Proteinuric Glomerular Disease (The AFFINITY Study)|
|Diabetic Kidney Disease||Atrasentan||NCT04573920||Phase 2 Basket Study of Atrasentan in Proteinuric Glomerular Disease (The AFFINITY Study)|
*Our programs are investigational therapies. An investigational therapy is a drug that has not yet been approved by the FDA. Efficacy and safety have not been established, and there is no guarantee that it will become commercially available for the use(s) under investigation. Participation in one of our clinical trials is the most appropriate way to access our investigational therapies.
The following is a list of resources for patients and families with reliable information related to kidney health and clinical trials.
ClinicalTrials.gov is a registry with information about the location of clinical trials, their design and purpose, and eligibility criteria. Search the database for Chinook trials or other clinical trials. www.clinicaltrials.gov
Center for Information and Research on Clinical Research Participation (CISCRP)
CISCRP is a nonprofit organization dedicated to educating and informing the public, patients, medical/research communities, the media, and policy makers about clinical research. www.ciscrp.org
American Association of Kidney Patients (AAKP)
AAKP is the oldest and largest, independent kidney patient organization in the U.S. dedicated to improving the lives and long-term outcome of kidney patients through education, advocacy, patient engagement and the fostering of patient communities. www.aakp.org
The following is a list of our advocacy partners, that can provide patients and families with reliable information related to kidney health and clinical trials.
The NKF is a major non-profit health organization focused on awareness, education, prevention and treatment of kidney disease. www.kidney.org
NephCure’s mission is to accelerate research for effective treatments for rare forms of Nephrotic Syndrome, and to provide education and support that will improve the lives of those affected by these protein-spilling kidney diseases. www.nephcure.org
A patient-centric non-profit organization focused on finding a cure for IgA Nephropathy through funding research, using patient advocacy to empower patients, and building a network of support. www.igan.org
Alport Syndrome Foundation is the leading independent non-profit organization in the United States educating and giving a voice to the Alport syndrome community through education, empowerment, advocacy and research. www.alportsyndrome.org
The Oxalosis & Hyperoxaluria Foundation (OHF) is dedicated to finding treatments and a cure for all forms of hyperoxaluria. www.ohf.org